Product Details

Neostigmine + Glycopyrrolate for Injection BP delivers a high-quality sterile combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose injectable combination is used for the reversal of neuromuscular blockade, combining a cholinesterase inhibitor with an anticholinergic agent in a single sterile solution for I.M./I.V. use.

The injection combines:

• Neostigmine Methylsulfate, a cholinesterase inhibitor that reverses non-depolarizing neuromuscular blockade by increasing acetylcholine availability at the neuromuscular junction, and
• Glycopyrrolate, an anticholinergic agent that counteracts the excessive muscarinic effects (such as bradycardia and increased secretions) caused by Neostigmine.

Anesthesiologists and healthcare providers commonly use this combination at the end of surgical procedures to reverse residual neuromuscular blockade from non-depolarizing muscle relaxants. Hospitals and surgical settings rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant sterile injectable combination
• Reverses non-depolarizing neuromuscular blockade
• Delivers combined cholinesterase-inhibitor and anticholinergic action
• Contains Neostigmine 0.5 mg + Glycopyrrolate 0.2 mg per mL
• For I.M./I.V. use
• Maintains a high-purity, sterile formulation
• Suits hospital and surgical settings